Eplerenone (Inspra) is an oral aldosterone receptor antagonist. Since its first approval in the United States in 2002, it has played an important role in post-heart failure management and hypertension treatment. It exerts unique therapeutic effects by selectively blocking the binding of aldosterone to mineralocorticoid receptors.
What are the Indications of Eplerenone (Inspra)?
Heart Failure after Myocardial Infarction
Eplerenone is indicated to improve the survival rate of adult heart failure patients who are clinically stable, symptomatic and have a reduced ejection fraction (≤40%) after acute myocardial infarction.
Treatment usually starts with an initial dose of 25 mg once daily, and the dose is gradually titrated up to the recommended target dose of 50 mg once daily within 4 weeks, depending on the patient's tolerance.
During the treatment period, serum potassium levels should be closely monitored, and individualized dose adjustments should be made based on the potassium values.
Hypertension
Eplerenone can be used for the treatment of hypertension in adults to lower blood pressure.
Lowering blood pressure helps reduce the risk of fatal and non-fatal cardiovascular events, especially stroke and myocardial infarction.
The recommended initial dose is 50 mg once daily. If blood pressure is not adequately controlled, the dose can be increased to 50 mg twice daily (i.e., 100 mg daily).
Studies have shown that daily doses exceeding 100 mg do not further enhance the antihypertensive effect but instead increase the risk of hyperkalemia; therefore, higher doses are not recommended.
This drug can be used alone or in combination with other types of antihypertensive agents to achieve the target blood pressure.
Dosage Forms and Characteristics of Eplerenone (Inspra)
Dosage Forms
Eplerenone tablets are available in two dosage strengths: 25 mg per tablet and 50 mg per tablet.
This formulation design facilitates flexible dose adjustment by physicians according to the patient's condition (e.g., heart failure or hypertension) and concomitant medication use (e.g., dose reduction is required when used with moderate CYP3A4 inhibitors).
Characteristics
Tablets of both strengths are yellow, diamond-shaped, biconvex film-coated tablets.
One side of the tablet is engraved with the letters "VLE", while the other side is engraved with the letters "NSR" and the corresponding dosage strength number "25" or "50".
This unique shape and clear marking help medical staff and patients accurately identify the medication and prevent accidental ingestion.
Storage and Handling of Eplerenone (Inspra)
Storage Methods
Eplerenone tablets should be stored at room temperature of 25°C (77°F). Short-term storage is permitted within a temperature range of 15°C to 30°C (59°F to 86°F).
Avoid exposure to moisture, excessive heat or direct sunlight.
The medication should be kept in its original packaging container and placed out of the reach of children.
Do not use the medication if it has passed its expiration date or if the packaging is damaged.
